Your search for oral corticosteroids returned 185 results

The study authors aimed to assess AE risk and complications of OCS use in patients with asthma since most studies only report them in non-asthmatic patients.

The Food and Drug Administration (FDA) has granted Fast Track designation to the investigational oral dual inhibitor, ASN002 (Asana BioSciences), for the treatment of moderate-to-severe atopic dermatitis.

Oral contraceptive use in women of reproductive age may increase the risk for lifetime asthma.

Children with asthma who experience chronic oral glucocorticoid exposure may have significant morbidities, including adrenal suppression, recurrent pneumonia, and behavioral problems.

Compared to the control group, patients who took four or more oral corticosteroid prescriptions had 1.29 times the odds of experiencing a new adverse effect within the year.

Ten days of treatment linked to increase in peak thrombin, velocity index, PAI-1, and vWF

Regarding knee osteoarthritis pain, intra-articular (IA) treatments were more efficacious than oral treatments possibly because of the integrated IA placebo effect, reported study authors at the 2013 ACR/ARHP Annual Meeting.

Drug-induced immunosuppression, particularly from oral corticosteroids, may limit response to COVID-19 vaccine

The first-in-class tyrosine kinase inhibitor masitinib decreased asthma exacerbations greater than placebo in patients with severe asthma uncontrolled by oral corticosteroids.

The designation was based on data from the Phase 2b PATHWAY trial that evaluated 3 doses of tezepelumab as add-on therapy in patients with a history of asthma exacerbations and uncontrolled asthma receiving inhaled corticosteroids/long-acting β-agonist with or without oral corticosteroids and additional asthma controllers vs placebo.